目的 探讨痛风舒胶囊联合非布司他治疗痛风的临床效果。方法 选取2016年6月-2018年12月天津市第一中心医院收治的86例痛风患者，随机分为对照组和治疗组，每组各43例。对照组口服非布司他片，40 mg/次，1次/d。治疗组在对照组基础上口服痛风舒胶囊，3粒/次，3次/d。两组均连续治疗3个月。观察两组的临床疗效，比较两组治疗前后主要症状体征改善情况、红细胞沉降率（ESR）、血清学指标和36项健康调查简表（SF-36）评分。结果 对照组和治疗组的总有效率分别是81.4%、95.3%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组关节疼痛评分、关节肿胀评分、关节畸形评分、受累关节数、痛风石最大直径均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组这些症状体征改善情况均优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组ESR值、尿酸、C反应蛋白（CRP）、白介素-1β（IL-1β）、丙二醛（MDA）水平均较治疗前显著降低，而超氧化物歧化酶（SOD）水平均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，ESR值、尿酸、CRP、IL-1β、MDA水平显著低于对照组，而SOD水平高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 痛风舒胶囊联合非布司他治疗痛风的整体疗效显著，有助于减轻患者症状，减少受累关节数，促进痛风石溶解，控制血尿酸水平，改善机体过度炎症状态，拮抗氧化应激，改善患者生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Tongfengshu Capsules combined with febuxostat in treatment of gout. Methods Patients (86 cases) with gout in Tianjin First Central Hospital from June 2016 to December 2018 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were po administered with Febuxostat Tablets, 40 mg/time, once daily. Patients in the treatment group were po administered with Tongfengshu Capsules, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the changes of main symptoms and signs improvement, ESR, serological indicators, and SF-36 scores in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.4% and 95.3%, respectively, and there were differences between two groups (P<0.05). After treatment, Joint pain score, joint swelling score, joint deformity score, number of involved joints and maximum diameter of topaz in two groups were significantly reduced compared with that before treatment, and there were differences in the same group (P<0.05). After treatment, the improvement of these symptoms and signs in the treatment group were better than those in the control group, and there were differences between two groups (P<0.05). After treatment, ESR, uric acid, CRP, IL-1β, and MDA in two groups were significantly reduced, but SOD was significantly increased, and there were differences in the same group (P<0.05). After treatment, ESR, uric acid, CRP, IL-1β, and MDA in the treatment group were significantly lower than those in the control group, but SOD was higher than that in the control group, and there were differences between two groups (P<0.05). Conclusion Tongfengshu Capsules combined with febuxostat has significant overall therapeutic effect in treatment of gout, and is helpful to reduce the symptoms of patients, and reduce the number of involved joints, and promote the dissolution of gout, and control the blood uric acid level, and also can improve the excessive inflammation of the body, and antagonize the oxidative stress, and improve the life quality, which has a certain clinical application value.

R977